research use only

Rotigotine Dopamine Receptor agonist

Cat.No.S4274

Rotigotine(N-0923) is a dopamine receptor agonist, used in the treatment of Parkinson's disease and restless legs syndrome.

Chemical Structure

Molecular Weight: 315.47

Jump to Mechanism of Action Solubility Chemical Information, Storage & Stability Specificity

Quality Control

Batch: S427401 DMSO]63 mg/mL]false]Ethanol]63 mg/mL]false]Water]Insoluble]false Purity: 99.97%

99.97

Related Targets	Adrenergic Receptor AChR 5-HT Receptor COX Calcium Channel Histamine Receptor GABA Receptor TRP Channel Cholinesterase (ChE) GluR MAO Beta Amyloid iGluR NMDAR P2 Receptor Trk receptor Serotonin Transporter Notch Norepinephrine Cannabinoid Receptor P-gp CaMK Opioid Receptor BACE Sigma Receptor FAAH Neurokinin Receptor OX Receptor CGRP Receptor CCK receptor
Related Products	MPTP Hydrochloride Trifluoperazine Trifluoperazine 2HCl Penfluridol SCH-23390 hydrochloride Domperidone SKF38393 HCl Sulpiride Azaperone C-DIM12 Levosulpiride Rotundine Piribedil PD128907 HCl Tiapride Hydrochloride (+/-)-tetrahydropalmatine Pridopidine Phenothiazine Pardoprunox (SLV-308) hydrochloride Vanoxerine dihydrochloride Alizapride HCl Thiethylperazine Melitracen hydrochloride Tavapadon Domperidone monomaleate Clebopride malate Raclopride DARPP32 Antibody [D14G22]

Chemical Information, Storage & Stability

Molecular Weight	315.47	Formula	C₁₉H₂₅NOS	Storage (From the date of receipt)	3 years-20°Cpowder
CAS No.	99755-59-6	Download SDF		Storage of Stock Solutions	1 year-80°Cin solvent 1 month-20°Cin solvent
Synonyms	N-0923			Smiles	CCCN(CCC1=CC=CS1)C2CCC3=C(C2)C=CC=C3O

Solubility

In vitro
Batch:

DMSO : 63 mg/mL (199.7 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Ethanol : 63 mg/mL

Water : Insoluble

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
Mass value Mass unit	Concentration value Concentration unit	Volume value Volume unit	Molecular weight (g/mol)

Dilution Calculator Molecular Weight Calculator

In vivo batch selection In vivo Batch:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Clear solution	5%DMSO 1 40%PEG300 2 5%Tween80 3 50%ddH2O Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	3.15mg/ml (9.99mM)	Taking the 1 mL working solution as an example, add 50 μL of 63 mg/ml clarified DMSO stock solution to 400 μL of PEG300, mix evenly to clarify it; add 50 μL of Tween80 to the above system, mix evenly to clarify; then continue to add 500 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results.
Clear solution	5% DMSO 1 95% Corn oil Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	0.45mg/ml (1.43mM)	Taking the 1 mL working solution as an example, add 50 μL of 9 mg/ml clear DMSO stock solution to 950 μL of corn oil and mix evenly. The mixed solution should be used immediately for optimal results.

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg

Average weight of animals: g

Dosing volume per animal: μL

Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO

% Tween 80

% ddH₂O

% DMSO

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Mechanism of Action

Targets/IC₅₀/Ki	Dopamine receptor ^[1]

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2024-05-22)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT02728947	Completed	Parkinson''s Disease	Luye Pharma Group Ltd.	May 2016	Phase 1
NCT02070796	Completed	Healthy	UCB Pharma SA\|UCB Pharma	February 2014	Phase 1
NCT01675024	Completed	Healthy	UCB Pharma	August 2012	Phase 1
NCT02786667	Unknown status	Parkinson Disease\|Apathy	University Hospital Grenoble	June 2012	Phase 3
NCT01565018	Completed	Healthy Volunteers	UCB Pharma\|Otsuka Pharmaceutical Co. Ltd.	March 2012	Phase 1

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):